Haemophilia trials in Poland
7 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
- Where
- Gdansk, Warsaw
- Age
- 2 years to 59 years
- People
- 60 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05987449 · EU 2023-503906-35-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Where
- Cracow, Gdansk, Warsaw
- Age
- 12 years and over
- People
- 360 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416604 · EU 2025-522435-33-00 - Phase 3Taking peopleA Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
- Where
- Gdansk, Lodz, Poznan, Warsaw
- Age
- 18 years and over
- People
- 84 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07830732 · EU 2026-525529-19-00 - Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
- Where
- Poznan, Warsaw, Wroclaw
- Age
- 1 year to 11 years
- People
- 85 worldwide
- Run by
- Sanofi
See details and how to joinNCT07285460 · EU 2025-521858-42-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- Where
- Gdansk, Warsaw
- Age
- 12 years and over
- People
- 138 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07416526 · EU 2025-522434-32-00 - Phase 1Taking peopleA Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
- Where
- Bialystok, Gdansk, Katowice, Lublin, Poznan, Warsaw
- Age
- 18 years to 64 years
- People
- 30 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07220564 · EU 2025-520490-38-00 - Phase 3Taking peopleEfficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- Where
- Warsaw
- Age
- 18 years and over
- People
- 35 worldwide
- Run by
- CSL Behring
See details and how to joinNCT06003387 · EU 2023-509590-23-00